Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) announced the advancement of CFT8919, a selective BiDAC degrader targeting EGFR L858R, into IND-enabling studies. The company expects to file for an IND by mid-2022, aiming to initiate a Phase 1/2 trial by year-end 2022. Preclinical data highlighting CFT8919's potency and selective activity against NSCLC will be presented at the Keystone Symposium. The company continues to progress its other drug candidates and aims to have four in clinical trials by the end of 2022.
C4 Therapeutics (Nasdaq: CCCC) appointed Lauren White as chief financial officer effective June 21, 2021, succeeding Bill McKee, who will remain as a part-time consultant. White brings over 20 years of financial experience from Novartis, where she held senior roles including global head of business planning. C4T aims to advance its portfolio of targeted protein degraders and is preparing to initiate its first clinical trial. The leadership change is anticipated to strengthen financial strategies while enhancing the company's mission of transforming cancer treatment.
C4 Therapeutics, Inc. (CCCC) reported first-quarter 2021 revenue of $7.4 million, up from $6.8 million in Q1 2020, attributed to collaborations with Roche, Biogen, and Calico. R&D expenses rose to $20.5 million from $16.3 million, driven by increased preclinical costs and workforce expansion. General and Administrative expenses jumped to $7.4 million from $2.8 million. The net loss was $21.0 million with a per-share loss of $0.49. C4T remains on track for upcoming clinical trials and IND submissions, maintaining a strong cash position of $346.0 million.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced its participation in two upcoming investor conferences. The first is the UBS Global Healthcare Conference on May 26, 2021, at 8:00 a.m. ET, followed by the Jefferies Healthcare Conference on June 1, 2021, at 10:30 a.m. ET. Live webcasts will be available on the company’s website, with replays archived for two weeks post-event. C4 Therapeutics focuses on developing small-molecule medicines that selectively degrade disease-causing proteins, offering a novel approach to treating cancer and other diseases.
C4 Therapeutics presented promising preclinical data for CFT7455, a MonoDAC degrader targeting IKZF1/3, indicating potential efficacy in treating multiple myeloma. High cereblon binding affinity (Kd = 0.9 nM) and rapid degradation of IKZF1/3 proteins were observed, leading to apoptotic cell death in multiple myeloma cell lines. In xenograft models, tumor regression was noted after treatment with CFT7455, both alone and in combination with dexamethasone. A Phase 1/2 clinical trial is expected to commence in 1H 2021, focusing on relapsed or refractory multiple myeloma and non-Hodgkin’s lymphomas.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced key milestones and financial results for 2020, reporting revenue of $33.2 million, an increase from $21.4 million in 2019. The net loss expanded to $66.3 million, while cash reserves increased to $372 million, projected to support operations through 2023. The FDA cleared the IND for lead candidate CFT7455, with a Phase 1/2 trial set to begin in 1H 2021. An IND for CFT8634 is planned for 2H 2021. The company expects to advance multiple programs by year-end 2022, bolstering its strategic position in hematologic malignancies.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced that a late-breaking abstract featuring preclinical data for its protein degrader CFT7455 has been selected for presentation at the AACR 2021 Annual Meeting, scheduled for April 10-15, 2021. CFT7455 targets IKZF1/3 to treat hematologic malignancies and has demonstrated potent tumor regression in IMiD-resistant multiple myeloma models. This signifies a key milestone for C4T in advancing innovative cancer treatments through targeted protein degradation, potentially overcoming limitations of traditional therapies.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a biopharmaceutical company innovating small-molecule medicines that degrade disease-causing proteins, has announced participation in two investor conferences in March 2021. They will present at the Cowen 41st Annual Health Care Conference on March 3 at 11:40 a.m. ET and the Guggenheim Targeted Protein Degradation Day on March 16 at 10:30 a.m. ET. Webcasts can be accessed on their website and will be available for two weeks post-event. C4T focuses on targeted protein degradation to treat cancer, neurodegenerative diseases, and more.
C4 Therapeutics (Nasdaq: CCCC) announced its participation in the BMO BioPharma Spotlight Series on February 18, 2021, at 10:30 a.m. ET. The panel discussion, titled “Ligating” Competitors for Collaboration in the Protein Degradation Space, will focus on next-generation technologies in protein degradation. A recording will be available for replay four hours post-event on the company’s website, archived for at least two weeks. C4T specializes in small-molecule medicines targeting disease-causing proteins, offering improved treatment options for cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC) announced FDA clearance of its IND application for CFT7455, an innovative oral MonoDAC targeting IKZF1/3, aimed at treating hematologic malignancies like multiple myeloma and non-Hodgkin lymphomas. This milestone allows the company to commence a Phase 1/2 clinical trial in the first half of 2021, following a positive 30-day safety review. The trial will evaluate CFT7455's safety, tolerability, and efficacy as a single agent and in combination therapies.